wyeth Goldman Sachs Healthcare Conference


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

wyeth Goldman Sachs Healthcare Conference

  1. 1. Goldman Sachs Annual Global Healthcare Conference Bernard Poussot President and Chief Executive Officer June 11, 2008
  2. 2. Forward-Looking Statement The statements in this presentation that are not historical facts are forward- looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to the NDA filings for Wyeth’s pipeline products referenced in this presentation), drug pricing and payment for Wyeth’s products by government and third-party payers, manufacturing, data generated on the safety and efficacy of Wyeth’s products, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in Wyeth’s periodic reports filed with the Securities and Exchange Commission, including Wyeth’s current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion in Wyeth’s annual report on Form 10-K under the caption quot;Item 1A, Risk Factors.quot; Wyeth assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. 2
  3. 3. Wyeth’s Goal: Generate Sustainable Growth In a Tumultuous Environment 1. Manage the Impact of Protonix on the Bottom Line 2. Achieve Full Potential of Core Products 3. Successfully Launch New Products 4. The Transforming Potential of R&D Optimize Diversification By Accelerating 5. International Expansion Continue Wyeth Transformation 6. 3
  4. 4. Manage the Impact of Protonix® on the Bottom Line Take Aggressive Measures to Mitigate the Impact of the Loss of Protonix to the Extent Possible Pro Forma EPS $3.35 to $3.49 (-1% to -5%)* n * Excludes Certain Significant Items 4
  5. 5. Optimize Growth Engines ® BMP-2 5
  6. 6. Successfully Introduce New Products Continued and Projected 2008 Launches Strong U.S. Acceptance; International Launches Taking Place Throughout 2008 Only Targeted RCC Agent with Overall Survival Benefit in Patients with Multiple Risk Factors Launch Just Underway – May 2008; Early Rx and Formulary Acceptance In-Line with Projections Improved Manufacturing Process Eliminates Risk of Viral Contamination and Increases Yields Future Standard for Relief of Opioid Side Effects; Full Launch Expected in July Flea and Tick Protection for Dogs and Flea Protection for Cats 6
  7. 7. The Transforming Potential of R&D Optimal Use of Three Technology Platforms … A Competitive Advantage for Wyeth Prevnar 13v n 4More Than Just Prevnar 7v for Infants 4Further Expansion into Infant Population … Especially International 4New Indication for Adult Population Alzheimer’s Disease n 4Potential to Transform Medicine and Wyeth 410 A.D. Compounds in Development at Wyeth 4Bapineuzumab Furthest Along Oncology n 4Two New Products Advanced to Phase 3 4Inotuzumab (CMC-544) –Treatment of Follicular Lymphoma 4Bosutinib (SKI-606) - Treatment of Chronic Myelogenous Leukemia Enhance Internal R&D Efforts with M&A: Technologies, Companies or Attractive Products 7
  8. 8. Optimize Diversification By Accelerating International Expansion Wyeth Revenue FY 2007 1Q 2008 48% 54% 46% 52% Int’l. U.S. Strong Growth From International Businesses 8
  9. 9. Optimize Diversification By Accelerating International Expansion 4100% ex-U.S.; Growing 19% 1Q08 4Operating Margins Similar to Pharmaceutical Business 4Continued Innovation to Offer Scientifically Advanced Nutritional Products 452% ex-U.S.; Growing 20% 1Q08 4Leadership in Pain, Cough/Cold and Vitamin/Nutritionals Categories 463% ex-U.S.; Growing 14% 1Q08 4Leading Biological/Vaccine Businesses 4Growing Strength in Companion Category e.g., ProMeris 9
  10. 10. Optimize Diversification By Accelerating International Expansion Enhanced Financial Dedicated Executive Support Management Leadership Focused/Accelerated Decision Making 10
  11. 11. Continue Wyeth Transformation Project Impact Level One n 4Cost Reduction to Absorb Protonix Losses Level Two n 4Business Model & Structure Refinement 4Enhance Productivity Initiatives - R&D - Manufacturing - Commercial - Administrative Level Three n 4Pharma Strategic Redesign 11
  12. 12. Effectively Manage Costs SG&A as a % of Revenue 40% 37.1% 36.0% 34.4% 34.5% 33.4% 35% 32.2% 31.6% 30.2% 30% 25% 2000 2001 2002 2003 2004 2005 2006 2007 … And More to Come From Project Impact 12
  13. 13. Leading Wyeth Forward Employing Multiple and Diverse Assets to Secure Future Growth 13